Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up
- PMID: 8453453
- DOI: 10.1093/brain/116.1.117
Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up
Abstract
An incidence cohort consisting of 308 multiple sclerosis patients was followed up repeatedly during at least 25 years of disease. A number of clinical factors were analysed with respect to their validity in assessing the long-term prognosis. Of the onset characteristics, the type of course was the most important, with primary progressive patients experiencing a much more severe course. In patients with an acute onset, low onset age, high degree of remission at first exacerbation, symptoms from afferent nerve fibres and onset symptoms from only one region (as compared with polyregional symptoms) of the central nervous system, were factors significantly associated with a favourable long-term prognosis. Of factors known 5 years after onset, a low number of affected neurological systems, a low neurological deficit score and a high degree of remission from the last bout were the most important favourable prognostic factors.
Similar articles
-
A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.Brain. 2012 Mar;135(Pt 3):900-11. doi: 10.1093/brain/awr336. Brain. 2012. PMID: 22366800
-
Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors.J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):148-52. doi: 10.1136/jnnp.67.2.148. J Neurol Neurosurg Psychiatry. 1999. PMID: 10406979 Free PMC article.
-
Prediction of outcome in multiple sclerosis based on multivariate models.J Neurol. 1994 Oct;241(10):597-604. doi: 10.1007/BF00920623. J Neurol. 1994. PMID: 7836963
-
Natural history of multiple sclerosis: risk factors and prognostic indicators.Curr Opin Neurol. 2007 Jun;20(3):269-74. doi: 10.1097/WCO.0b013e32812583ad. Curr Opin Neurol. 2007. PMID: 17495619 Review.
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
Cited by
-
Predictors of disability worsening in clinically isolated syndrome.Ann Clin Transl Neurol. 2015 May;2(5):479-91. doi: 10.1002/acn3.187. Epub 2015 Mar 27. Ann Clin Transl Neurol. 2015. PMID: 26000321 Free PMC article.
-
Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis.Front Neurol. 2020 Sep 2;11:944. doi: 10.3389/fneur.2020.00944. eCollection 2020. Front Neurol. 2020. PMID: 32982947 Free PMC article.
-
The Swedish MS registry – clinical support tool and scientific resource.Acta Neurol Scand. 2015;132(199):11-9. doi: 10.1111/ane.12425. Acta Neurol Scand. 2015. PMID: 26046553 Free PMC article. Review.
-
Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide.Front Immunol. 2022 Sep 27;13:991291. doi: 10.3389/fimmu.2022.991291. eCollection 2022. Front Immunol. 2022. PMID: 36238285 Free PMC article. Review.
-
Differentiation of multiple sclerosis subtypes: implications for treatment.CNS Drugs. 2002;16(6):405-18. doi: 10.2165/00023210-200216060-00004. CNS Drugs. 2002. PMID: 12027786 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical